Post-marketing surveillance of Vadadustat in patients with anemia in chronic kidney disease for long-term efficacy and safety
Latest Information Update: 15 Nov 2022
At a glance
- Drugs Vadadustat (Primary)
- Indications Renal failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms VIOLET survey
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 14 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 06 May 2021 Status changed from not yet recruiting to recruiting.
- 01 Dec 2020 New trial record